1-8 of 8
David Vesole, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience.

Anuj Mahindra, MD, David Vesole, MD, PhD, Matt E. Kalaycio, MD, Jorge Vela-Ojeda, MD, Smriti Shrestha, MS, MA, Mei-Jie Zhang, PhD, Angela Dispenzieri, MD, Gustavo A. Milone, MD, Sagar Lonial, MD, Parameswaran N. Hari, MD, MS
Journal: Blood
Blood (2009) 114 (22): 532.
https://doi.org/10.1182/blood.V114.22.532.532
Published: 2009
Journal Articles

Therapy Related Leukemia in HIV Patients after Treatment for Non-Hodgkin Lymphoma

Jed Katzel, MD, Sanford Kempin, MD, David Vesole, MD, Portia Lagmay-Fuentes, NP, William Cook, MD, Frederick Siegal
Journal: Blood
Blood (2008) 112 (11): 5284.
https://doi.org/10.1182/blood.V112.11.5284.5284
Published: 2008
Journal Articles

Impact of Prior Lenalidomide Treatment on Peripheral Blood Stem Cell (PBSC) Mobilization in Untreated Multiple Myeloma (MM) Patients.

Amitabha Mazumder, MD, Jonathan Kaufman, MD, Sagar Lonial, MD, Sundar Jagannath, MD, David Vesole, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 3612.
https://doi.org/10.1182/blood.V110.11.3612.3612
Published: 2007
Journal Articles

Current Staging Systems Are Inadequate Predictors of Treatment Failure after Autologous Hematopoietic Stem Cell Transplants (AuHCT) in Multiple Myeloma (MM).

Parameswaran Hari, MD, Waleska PeĢrez, MPH, Mei-Jie Zhang, PhD, Christopher Bredeson, MD, MSc, Gustavo Milone, MD, Donna Reece, MD, Vivek Roy, MD, David Vesole, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 938.
https://doi.org/10.1182/blood.V110.11.938.938
Published: 2007
Journal Articles

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

S. Vincent Rajkumar, MD, Susanna Jacobus, MS, Natalie Callander, MD, Rafael Fonseca, MD, David Vesole, MD, PhD, Michael Williams, MD, Rafat Abonour, MD, David Siegel, MD, Philip Greipp, MD
Journal: Blood
Blood (2007) 110 (11): 74.
https://doi.org/10.1182/blood.V110.11.74.74
Published: 2007
Journal Articles

Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

David Siegel, MD, PhD, Sundar Jagannath, MD, Amitabha Mazumder, MD, David Vesole, MD, Ivan Borrello, MD, Jens Sydor, PhD, Jim Wright, PhD, Jon Patterson, BS, Emmanuel Normant, PhD, Julian Adams, PhD, Kenneth Anderson, MD, David Grayzel, MD, Paul Richardson, MD
Journal: Blood
Blood (2006) 108 (11): 3579.
https://doi.org/10.1182/blood.V108.11.3579.3579
Published: 2006
Journal Articles

A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

S. Vincent Rajkumar, MD, Susanna Jacobus, MS, Natalie Callander, MD, Rafael Fonseca, MD, David Vesole, MD, Philip Greipp, MD
Journal: Blood
Blood (2006) 108 (11): 799.
https://doi.org/10.1182/blood.V108.11.799.799
Published: 2006
Journal Articles

A Phase II Study of PS-341 for Patients with High Risk, Newly Diagnosed Multiple Myeloma: A Trial of the Eastern Cooperative Oncology Group (E2A02).

Angela Dispenzieri, MD, Emily Blood, MS, David Vesole, MD, Rafael Fonseca, MD, Natalie Callander, MD, Philip R. Greipp, MD
Journal: Blood
Blood (2005) 106 (11): 2546.
https://doi.org/10.1182/blood.V106.11.2546.2546
Published: 2005